1	Impact of a National Immunisation Program on herpes zoster incidence in
2	Australia
3	
4	Running title: Population impact of a zoster immunisation program
5	
6	Jialing Lin ^{a,} *, Timothy Dobbins ^a , James G Wood ^a , Carla Bernardo ^b , Nigel P Stocks
7	^b , Bette Liu ^a
8	
9	^a School of Population Health, University of New South Wales, Sydney, NSW 2052,
10	Australia.
11	^b Discipline of General Practice, Adelaide Medical School, University of Adelaide,
12	Adelaide, SA 5005, Australia.
13	
14	*Corresponding author.
15	E-mail address: jialing.lin@student.unsw.edu.au (J. Lin), t.dobbins@unsw.edu.au (T.
16	Dobbins), james.wood@unsw.edu.au (J. Wood), carla.bernardo@adelaide.edu.au (C.
17	Bernardo), nigel.stocks@adelaide.edu.au (N.P. Stock), bette.liu@unsw.edu.au (B.

18 Liu).

19 Summary

- 20 *Objectives:* To evaluate the impact of the National Herpes Zoster (zoster)
- 21 Immunisation Program in Australia on zoster incidence.
- 22 *Methods:* Ecological analysis of zoster incidence related to timing of implementation
- 23 of the national program in vaccine-targeted (70-79 years) and non-targeted age groups
- 24 (60-69 and 80-89 years) during January 2013-December 2018 was estimated using
- 25 interrupted time-series analyses.
- 26 Results: Prior to program commencement (Jan 2013 to Oct 2016) in patients aged
- 27 60-69, 70-79 and 80-89 years, incidence was mostly stable averaging respectively 7.2,
- 28 9.6 and 10.8 per 1000 person-years. In the two years following program
- 29 commencement, incidence fell steadily in those aged 70-79 years, with an estimated
- decrease of 2.25 (95% CI: 1.34, 3.17) per 1000 person-years per year, with women
- having a greater decrease than men (2.83 versus 1.68, p-interaction<0.01). In the two
- 32 non-vaccine-program-targeted age groups there was no evidence of reduction in
- 33 zoster incidence: 60-69 years, 0.46 (95% CI: -0.46, 1.38) and 80-89 years, 0.11 (95%
- 34 CI: -1.64, 1.87).
- 35 *Conclusions:* Two years after implementation, an estimated 7000 zoster cases were
- 36 prevented through the national program. With known waning vaccine efficacy,
- 37 continued surveillance is needed to ensure these early reductions in incidence are

38 sustained.

- 40 *Keywords:* Immunisation, herpes zoster, general practitioner, electronic medical
- 41 records

42 Introduction

43 Herpes zoster (zoster) is a painful rash that occurs following reactivation of the 44 varicella zoster virus. It is more frequently observed in older people and those who are immunocompromised.¹ It can cause prolonged and severe pain leading to 45 significant health problems including difficulty mobilising and also psychological 46 conditions, such as anxiety, depression, and even social isolation.² The lifetime risk of 47 acquiring zoster is 20-30%, with incidence increasing with age.^{3, 4} A recent study 48 49 reported annual age-specific zoster incidence of 1.8 per 1000 persons for those aged 50 under 25 years, 6.3 per 1000 for 50-59 year olds, and 19.9 per 1000 for those aged 80 years and over in Australia.⁵ 51 52 Two effective zoster vaccines are currently registered; one is a live-attenuated 53 vaccine with reported one-dose efficacy of 51.3% against zoster in adults aged 60

54 years and over⁶ and the other, a recombinant subunit adjuvanted vaccine with

two-dose efficacy of 97.2% against zoster in adults aged 50 years and over⁷. In

56 Australia, the live-attenuated vaccine was registered in 2007 but not available until

57 2013 by private prescription. The recombinant subunit adjuvanted vaccine was

registered in 2018 but is not available yet. Since November 2016 in Australia under a

59 National Herpes Zoster Immunisation Program, a single dose of the live-attenuated

⁶⁰ zoster vaccine has been offered to adults aged 70 years with a time-limited catch-up

61 program for those aged 71-79 years until 2021.⁸ Evaluating the impact of this national

62 program on zoster incidence has been limited by the fact that in Australia zoster is not

notifiable in all states and territories,⁹ and the reliability of reporting of zoster to public

64 health units is uncertain with notifications likely to underestimate true rates. Also,

65 internationally there is only one other impact evaluation of a national zoster program.¹⁰

66 Therefore, in order to add to the limited knowledge regarding zoster vaccine 67 program effects at a population level, the aim of this study was to evaluate the impact 68 of the National Herpes Zoster Immunisation Program on zoster incidence by using a 69 large national general practice dataset.

70

71 Methods

72 Ethics

- 73 This study was approved by the MedicineInsight Independent External Data
- Governance Committee (reference number 2018-015) and the University of New
- 75 South Wales Human Research Ethics Committee (No. HC180939).
- 76

77 Data source

78 MedicineInsight is a large, longitudinal general practice dataset with data extracted 79 from electronic medical records in general practices across Australia. Participating 80 general practices consent to provide de-identified data on an ongoing basis to the 81 MedicineInsight program. The program was developed and is managed by NPS 82 MedicineWise. The dataset contains separate tables with patient demographic records, 83 diagnoses, reasons for encounter, and prescriptions made during patient encounters. 84 Each record is dated and is assigned a unique patient identifier. This enables records 85 related to the same individual to be linked. More details of this dataset are available elsewhere.^{11, 12} In this study, we used an extract containing records from 25% of 86 patients randomly selected from the whole dataset with complete records to 31st 87 88 December 2018.

89

90 Study population

91 For this analysis we used presentations recorded in the MedicineInsight dataset from 1st January 2013- 31st December 2018 in adults turning 60-89 years old. As 92 93 people in Australia have unrestricted choice when accessing general practice services, 94 we needed to define a regular attender for a population denominator to estimate incidence. As done previously¹³, we defined our main study population as those who 95 96 had records of attending the same practice on at least one non-administrative visit 97 each year in the previous two years. Administrative visits were those that only 98 involved administrative notes, emails, faxes, file reviews, phone calls, and phone 99 messages. In addition, patients recorded as deceased in that year, or with missing data 100 on year of birth, sex or zoster diagnosis date were excluded from the study population. 101

102 Definition of herpes zoster cases

103 For our main analyses we defined a case as having a diagnosis of zoster if they had 104 a term indicating zoster (zoster, HZ, shingles, zona) in either the encounter reason or 105 diagnosis tables but not one of the exclusion terms. Exclusion terms included a word 106 indicating only a possible/suspected diagnosis, or a term indicating the encounter was 107 for vaccination, advice only, or related to a family member (see Appendix Table 1 for 108 full list). Encounters where there was a record of a zoster vaccine administered in the 109 immunisation table on the same date were also excluded as cases. As both the 110 encounter reason and diagnosis tables were free text, to include possible misspellings, 111 we used the SPEDIS function with cost \leq 30 in SAS to identify closely related 112 spellings to our zoster terms. 113

114 Data analysis

115 All records that met the case definition with the same patient identifier and record 116 date were considered duplicates and removed before data analysis. If participants had 117 more than one record of a zoster diagnosis over the study period, records that were 118 separated by more than 180 days during the observation period were considered as distinct episodes of zoster¹⁴ and contributed to counts of events. For each calendar 119 120 year of data, we divided participants into three groups based on the age they turned in 121 that year: 60-69, 70-79 (targeted for vaccination), and 80-89 years old. Zoster 122 incidence in each month and the year of observation was estimated by calculating the 123 number of zoster episodes recorded in that period divided by person-years of the 124 study population meeting the regular attender definition in that year.

For estimating annual zoster incidence before and after the national program, we separated data into the three-year time period from November 2013 to October 2016 which was considered "before the program", and the two-year period from November 2016 to October 2018 which was considered "after the program". We estimated zoster incidence in each period (before and after the program) and the relative and absolute reductions in incidence comparing the periods, stratified by age and sex. We also

131 calculated incidence before and after the program in those 70-79 years by practice jurisdiction, remoteness status¹⁵ and area-level socioeconomic disadvantage using the 132 index of relative socioeconomic advantage and disadvantage $(IRSAD)^{16}$. 133 We used an interrupted time-series model¹⁷ to further investigate the effect of the 134 135 national program on zoster incidence. We defined January 2013-October 2016 as the 136 pre-program period and November 2016-December 2018 as the post-program period. 137 A segmented regression was used, including terms to estimate the base level of 138 incidence at the beginning of the series, the pre-program trend in incidence, the 139 change in level of incidence immediately after the program and the change in trend of 140 incidence after the program. We assessed serial autocorrelation graphically and via 141 the Durbin-Watson statistic, accounting for autocorrelation where necessary by 142 including an auto-regressive term. Model assumptions were checked using graphical 143 summaries of residuals. In addition, we calculated the total number of zoster cases 144 averted in the vaccine-targeted age group in Australia by applying our estimates of absolute reduction to population estimates from the 2016 census.¹⁸ 145 146 All analyses were conducted with SAS v. 9.4 (SAS Institute Inc. Cary, North 147 Carolina, USA).

148

149 Sensitivity analysis

150 In the first sensitivity analysis we re-defined the study population, to be consistent with the Royal Australian College of General Practitioners (RACGP)¹⁹ which defines 151 152 a regular attender as a patient who attended the same practice for at least three 153 non-administrative visits on different days within the last two years. For the second, 154we broadened the definition of a zoster case by including those with a prescription 155 record of a zoster-specific antiviral (see Appendix Table 2 for details). This included 156 acyclovir (800 mg) with 35 tablets, valacyclovir (500 mg) with 42 tablets, or famciclovir (250 mg) with 21 tablets.²⁰ 157 158

159 **Results**

160	For each analysis year, there were: between 50814 and 62677 regular attenders
161	aged 70-79 years, 82248 to 89542 aged 60-69 years, and 27166 to 29866 aged 80-89
162	years. For the vaccine-targeted age group (70-79 years), there were 2439 patients who
163	met the zoster case definition over the five-year period, Nov 2013-Oct 2018. For the
164	two non-vaccine-targeted age groups, 60-69 and 80-89 years of age, the
165	corresponding figures were 1495 and 550, respectively.
166	Table 1 shows the crude average annual incidence of zoster before and after
167	program commencement. Zoster incidence per 1000 person-years before and after the
168	program was 9.5 versus 7.5 for those 70-79 years, 7.7 versus 8.3 for those 60-69 years
169	and 9.0 versus 9.3 for those 80-89 years. Among those aged 70-79 years the absolute
170	reduction in incidence was 2.0 per 1000 person-years or a relative reduction of 21%.
171	Such falls were not observed in either the 60-69 or the 80-89 years age groups.
172	Women had consistently higher incidence than men in all age groups both before and
173	after program commencement and falls in incidence were observed for both men and
174	women aged 70-79 years. Among the vaccine-targeted population (aged 70-79 years)
175	we also found incidence decreased after the program in all remoteness and
176	socioeconomic status categories, and in most jurisdictions, except the Northern
177	Territory and Western Australia (Appendix Table 3).
178	Trends in zoster incidence pre- and post- program by age group are shown in
179	Figure 1. Prior to program commencement in patients aged 60-69, 70-79 and 80-89
180	years, incidence was mostly stable averaging respectively 7.2, 9.6 and 10.8 per 1000
181	person-years. However, following the program commencement, the incidence fell
182	steadily in those aged 70-79 years.
183	From the interrupted time-series analysis, the trend in zoster incidence in the
184	vaccine-targeted age group decreased by 2.25 (95% CI: 1.34, 3.17) per 1000
185	person-years per year (Table 2). Women had a greater decrease than men (2.83 versus
186	1.68, test for interaction <0.01). By contrast, there was no evidence of reductions in
187	zoster incidence trends for the two non-vaccine-targeted age groups.
188	

189 Sensitivity analyses

190	Use of the RACGP definition of a regular attender did not change the patterns in
191	incidence. In those aged 70-79 years the post-program decrease in incidence was 1.98
192	(95% CI: 1.13, 2.84) per 1000 person-years per year whilst there was no change in
193	those 60-69 and those 80-89 years (see Appendix Table 4).
194	Using the broader zoster case definition resulted in higher incidences but the
195	patterns were similar. Before and after the program for those aged 60-69, 70-79,
196	80-89 years respectively: 9.4 versus 10.0, 11.5 versus 9.1, 11.0 versus 11.2 per 1000
197	person-years. There was also evidence of a reduction in incidence trends in the 70-79
198	years age group (reduction: 2.45 (95% CI: 1.63, 3.27) per 1000 person-years per year)
199	but not in either the 60-69 or the 80-89 years age groups (see Appendix Table 5).
200	
0.04	

201 Discussion

To the best of our knowledge, this is the first study to estimate the impact of the National Zoster Immunisation Program on zoster incidence in Australia. We found that in the two years after implementation, zoster incidence decreased by 2.25 per 1000 person-years per year or by about 40% from pre-program levels in the vaccine-targeted population (those aged 70-79 years); no significant falls were recorded in those aged 60-69 and 80-89 years.

208 Our findings are consistent with studies in other countries and regions that have 209 also implemented and evaluated zoster immunisation programs with live-attenuated 210 zoster vaccines. England introduced a zoster immunisation program for 70 year olds with phased catch-up for those 71-79 years in September 2013.¹⁰ After three years, 211 212 vaccine coverage was reported as 60% in the vaccine-targeted population, and zoster 213 incidence was reported to decrease by 3.1 per 1000 person-years. In the Canadian 214 province of Ontario, a zoster immunisation program was introduced in September 2016 for adults aged 65-70 years.²¹ Results of a national survey showed vaccine 215 uptake was 21% among participants aged \geq 50 years in 2016²² and the monthly 216

217 incidence of medically-attended zoster in the 2 years after program implementation

was reported to decrease by 1 per 10,000 population²¹.

Some of the differences in the estimated impact of the zoster immunisation 219 220 program in Australia compared to other regions could be due to differences in zoster 221 case ascertainment used in this study and vaccine coverage achieved. Estimates of 222 zoster vaccine uptake in Australia are limited. A report based on data from the 223 Australian Immunisation Register suggested that cumulative vaccine coverage 23 224 months after program commencement in Australia was 31.2% among adults aged 70-79 years but this is considered an underestimate due to underreporting.²³ Using 225 226 this same general practice database (MedicineInsight) in a separate study we have 227 estimated higher coverage (47%) in the targeted population 2 years after program 228 commencement.¹³

229 Women had both higher incidence of zoster but also greater reductions in incidence 230 than men following program implementation, and this might be explained by higher vaccine uptake in women than men.^{13, 23} This sex difference was also observed in the 231 Canadian study.²¹ The fall in incidence post-program was also observed to be 232 233 relatively uniform across Australian regions (by remoteness) and socioeconomic 234groups, and also in most jurisdictions, although not in the Northern Territory and 235 Western Australia. The lack of a reduction in incidence in the Northern Territory may 236 be due to the small number of participating practices in our sample and therefore a 237 lack of power to detect a difference; although vaccine coverage in the Northern Territory is also reported to be substantially lower²³. The lack of change in incidence 238 239 detected in Western Australia is more difficult to explain as coverage is reportedly similar to other jurisdictions²³ and further investigation is required to confirm this 240 241 difference.

Study strengths include the use of a large national general practice dataset of electronic medical records allowing us sufficient numbers of cases in age groups to investigate changes over time. However, there are some limitations. Firstly, we only studied people attending GPs so zoster cases diagnosed in settings such as emergency

246 departments or hospitals or at GPs not participating in the MedicineInsight database 247 would be missed but this proportion is likely to be small and unlikely to differ 248 between the pre- and post-program periods examined. Secondly, there is the potential 249 for misclassification of zoster cases and we were unable to validate the case records. 250 However, we used the same case definition consistently over time and in different age 251 groups and we included a range of terms and misspellings to improve detection and 252exclude questionable cases. The fact we observed a fall in incidence coinciding with 253 the time of program implementation and only in vaccine-targeted age groups suggest 254 that our definition was valid.

255

256 Conclusion

257 In summary, our study shows that the recently implemented National Herpes Zoster 258 Immunisation Program in Australia has had a significant impact on reducing zoster 259incidence among the vaccine-targeted population and that the level of reduction 260 appears to be consistent with other regions in the world that have similar programs in place, given differences in vaccine uptake. Based on Australian census data²⁴ for the 261 262 population aged 70-79 years (N=1,540,376), we estimate about 7000 zoster cases 263 would have been averted two years after the program commenced. Given the known waning of vaccine efficacy for the live-attenuated vaccine,²⁵ longer-term evaluation of 264 265 this program is also needed to ensure that zoster incidence continues to decrease. 266

267 Acknowledgements

We thank the NPS MedicineWise MedicineInsight for providing the data for this study. J. Lin is supported by the University International Postgraduate Awards under a UNSW Tuition Fee Scholarship and a School of Population Health Stipend

271 Scholarship. B. Liu is supported by an NHMRC Fellowship.

272

273 **Declaration of Competing Interest**

274 None.

275 **References**

276	1.	Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9(3):361.
277	2.	Lang P-O, Aspinall R. Vaccination in the Elderly: What Can Be Recommended? Drugs
278		& Aging 2014; 31 (8):581-99.
279	3.	Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?
280		<i>Lancet Infect Dis</i> 2004; 4 (1):26-33.
281	4.	Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001;32(10):1481-6.
282	5.	MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A. Increasing
283		trends of herpes zoster in Australia. PLoS ONE 2015;10(4):e0125025.
284	6.	Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A
285		Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. N Engl J
286		<i>Med</i> 2005; 352 (22):2271-84.
287	7.	Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al.
288		Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. N Engl J
289		<i>Med</i> 2015; 372 (22):2087-96.
290	8.	Australian Government Department of Health. National Immunisation Program Schedule.
291		2017 [cited 2020 5 June]. Available from:
292		https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/nati
293		onal-immunisation-program-schedule.
294	9.	Sheel M, BeardI F, QuinnII H, Dey A, Kirk M, Koehler A, et al. Australian vaccine
295		preventable disease epidemiological review series: varicella-zoster virus infections,
296		1998–2015. J Commun Dis Intell 2016;40(1):E189-E93.
297	10.	Amirthalingam G, Andrews N, Keel P, Mullett D, Correa A, de Lusignan S, et al.
298		Evaluation of the effect of the herpes zoster vaccination programme 3 years after its
299		introduction in England: a population-based study. Lancet Public Health
300		2018; 3 (2):e82-e90.
301	11.	NPS MedicineWise. MedicineInsight Data Book version 2.2. June 2019 [cited 2020 5
302		June]. Available from:
303		https://www.nps.org.au/assets/NPS/pdf/MedicineInsight_databook_June-2019.pdf.
304	12.	Busingye D, Gianacas C, Pollack A, Chidwick K, Merrifield A, Norman S, et al. Data
305		Resource Profile: MedicineInsight, an Australian national primary health care database.
306		Int J Epidemiol 2019;48(6):1741-h.
307	13.	Lin J, Wood JG, Bernardo C, Stocks NP, Liu B. Herpes zoster vaccine coverage in
308		Australia before and after introduction of a national vaccination program. Vaccine
309		2020; 38 (20):3646-52.
310	14.	Donahue JG, Choo PW, Manson JE, Platt R. The Incidence of Herpes Zoster. Arch
311		Intern Med 1995;155(15):1605-9.
312	15.	Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS). 2018
313		[cited 2020 5 June]. Available from:
314		https://www.abs.gov.au/websitedbs/D3310114.nsf/home/Australian+Statistical+Geograp
315		hy+Standard+(ASGS).
316	16.	Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA) 2016. March
317		2018 [cited 2020 5 June]. Available from:

318		https://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/756EE3DBEFA869EFCA258
319		259000BA746/\$File/SEIFA%202016%20Technical%20Paper.pdf.
320	17.	Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of
321		interrupted time series studies in medication use research. J Clin Pharm Ther
322		2002; 27 (4):299-309.
323	18.	Australian Bureau of Statistics. 2016 Census. 2017 [cited 2020 5 June]. Available from:
324		https://www.abs.gov.au/websitedbs/D3310114.nsf/Home/Assuring%20Census%20Data
325		<u>%20Quality</u> .
326	19.	The Royal Australian College of General Practitioners. Standards for general practices
327		(4th edition). 2015 [cited 2020 5 June]. Available from:
328		https://www.racgp.org.au/download/documents/Standards/standards4thedition.pdf.
329	20.	Liu B, Heywood AE, Reekie J, Banks E, Kaldor JM, McIntyre P, et al. Risk factors for
330		herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study.
331		Epidemiol Infect 2015; 143 (13):2871-81.
332	21.	Martins D, McCormack D, Tadrous M, Gomes T, Kwong JC, Mamdani MM, et al.
333		Impact of a publicly funded herpes zoster immunization program on the burden of
334		disease in Ontario, Canada: a population-based study. [published online ahead of print,
335		2020 Jan 10]. Clin Infect Dis 2020:ciaa014. doi: 10.1093/cid/ciaa014.
336	22.	Public Health Agency of Canada. Vaccine uptake in Canadian adults : results from the
337		2016 Adult National Immunization Coverage Survey (aNICS). 2018 [cited 2020 5 June].
338		Available from:
339		http://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-222-2018-eng.pdf.
340	23.	National Centre for Immunisation Research and Surveillance. Exploratory analysis of the
341		first 2 years of adult vaccination data recorded on AIR. 2019 [cited 2020 5 June].
342		Available from:
343		http://ncirs.org.au/sites/default/files/2019-12/Analysis%20of%20adult%20vaccination%
344		20data%20on%20AIR_Nov%202019.pdf.
345	24.	Australian Bureau of Statistics. Patient Experiences in Australia: Summary of Findings,
346		2017-18. 2018 [cited 2020 5 June]. Available from:
347		https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4839.02017-18?OpenDocum
348		<u>ent</u> .
349	25.	Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al.
350		Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015;60(6):900-9.

- 352 **Table 1** Crude annual incidence of herpes zoster per 1000 person-years before and
- after implementation of the National Herpes Zoster Immunisation Program among
- attending General Practices in Australia, by age and sex.

	Before program	After program	
Age, sex	(Nov 2013-Oct 2016)	(Nov 2016-Oct 2018)	
60-69 y			
Overall	7.7 (1979/256157)	8.3 (1495/179146)	
Men	6.3 (753/119315)	6.6 (547/82576)	
Women	9.0 (1226/136842)	9.8 (948/96570)	
70-79 y			
Overall	9.5 (1518/160727)	7.5 (921/122779)	
Men	8.4 (626/74847)	6.6 (381/57692)	
Women	10.4 (892/85880)	8.3 (540/65087)	
80-89 y			
Overall	9.0 (756/83874)	9.3 (550/59234)	
Men	7.7 (272/35392)	8.9 (224/25130)	
Women	10.0 (484/48482)	9.6 (326/34104)	

355 Incidence is shown by the incidence rate (total number of zoster episodes/total number of

356 person-years).

- **Table 2** Impact of the National Herpes Zoster Immunisation Program on trends in
- 358 incidence of herpes zoster among patients attending General Practices in Australia, by
- age and sex.

	Pre-program trend ^a		Change in trend	
Age, sex		Post-program trend ^b	Estimate (95% CI)	<i>P</i> -value
60-69 y				
Overall	0.18 (-0.23, 0.59)	-0.28 (-1.05, 0.50)	-0.46 (-1.38, 0.46)	0.3
Men	-0.08 (-0.45, 0.29)	-0.20 (-1.17, 0.78)	-0.12 (-1.13, 0.88)	0.8
Women	0.22 (-0.35, 0.80)	-0.59 (-1.78, 0.61)	-0.81 (-2.19, 0.57)	0.3
70-79 y				
Overall	0.09 (-0.31, 0.48)	-2.16 (-2.94, -1.40)	-2.25 (-3.17, -1.34)	< 0.001
Men	-0.09 (-0.53, 0.35)	-1.77 (-2.93, -0.62)	-1.68 (-2.87, -0.49)	< 0.001
Women	0.06 (-0.50, 0.62)	-2.77 (-4.09, -1.45)	-2.83 (-4.26, -1.40)	< 0.001
80-89 y				
Overall	-0.13 (-0.89, 0.62)	-0.25 (-1.75, 1.26)	-0.11 (-1.87, 1.64)	0.9
Men	-0.27 (-1.20, 0.66)	-0.16 (-2.12, 1.82)	0.11 (-2.12, 2.35)	0.9
Women	-0.08 (-1.04, 0.89)	-0.67 (-2.93, 1.60)	-0.59 (-3.05, 1.87)	0.6

360 CI, incidence interval.

^aPre-program trend (per 1000 person-years per year) is calculated over Jan 2013-Oct 2016


and shown by estimate (95% CI).

^bPost-program trend (per 1000 person-years per year) is calculated over Nov 2016- Dec 2018

and shown by estimate (95% CI).

365 Figure legend

- Fig. 1. Monthly incidence of herpes zoster per 1000 person-years among patients aged
- 367 (A) 60-69, (B) 70-79 and (C) 80-89 years old attending General Practices during Jan
- 368 2013-Dec 2018 in Australia.



Month-year